Central effects of Fingolimod;Efectos del fingolimod en el sistema nervioso central

Revista de Neurologia

Volumn 59, Issue 3, 2014, Pages 121-128

  Cruz, Vítor T ^a,b   Fonseca, Joaquim ^c  

^a Pediatrics Department   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c Oncology Department   (Portugal)

Author keywords

Astrocytes; Central effects; Fingolimod; Multiple sclerosis; Neurons; Oligodendrocytes

Indexed keywords

FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; NEUROPROTECTIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DEMYELINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; GLIOSIS; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GLIA; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; MOUSE MUTANT; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVOUS SYSTEM DEVELOPMENT; NEUTROPHIL CHEMOTAXIS; RAT; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BLOOD-BRAIN BARRIER; CHEMOTAXIS, LEUKOCYTE; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC MEMORY; MICE; MICE, KNOCKOUT; MICE, NEUROLOGIC MUTANTS; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROGENESIS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PROPYLENE GLYCOLS; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; T-LYMPHOCYTE SUBSETS;

EID: 84905240043     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5903.2013556     Document Type: Review

References (80)

1. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
2. Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012; 69: 1259-69.
3. Radue EW, Barkhof F, Cohen J, Holdbrook F, Francis G, Kappos L. MRI analyses in RRMS patients with highly active disease: results from FREEDOMS and TRANSFORMS phase 3 studies. Neurology 2012; 78 (Meeting Abstracts 1): P01.134.
4. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013; 260: 2023-32.
5. Calabresi PA, Radue EW, Goodin D, Jeffery D, Reder AT, Vollmer T, et al. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study). Presented at the 65th AAN annual meeting Emerging Science Session, 25th April 2012.
6. Antel J, Montalban X, O'Connor P, De Vera A, Cremer M, Sfikas N, et al. Long-term (7-year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Neurology 2012; 78 (Meeting Abstracts 1): P01.129.
7. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
8. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-9.
9. Montalban X, Barkhof F, Comi G, Hartung H, Kappos L, Khatri B, et al. Long-term comparison of fingolimod with interferon-beta-1a: results of 4.5-year follow-up from the extension phase III TRANSFORMS study. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 11th October 2012, Lyon, France (Poster P517). 2012.
10. O'Connor P, Polman C, Hohlfeld R, Selmaj K, Olsson T, Agoropoulou C, et al. Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 11th October 2012, Lyon, France (Poster P523). 2012.
11. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 2013; 13: 138.
12. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-25.
13. Chun J, Hartung H-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
14. Garcia-Merino JA, Sanchez AJ. Mecanismos basicos de accion del fingolimod en relacion con la esclerosis multiple. Rev Neurol 2012; 55: 31-7.
15. Cervera C. Infections y fingolimod. Rev Neurol 2012; 55: 227-37.
16. Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res 2013; 67: 1-9.
17. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007; 55: 1656-67.
18. Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and dose-dependent responses of adult human mature oligo- dendrocytes to fingolimod. Am J Pathol 2008; 173: 1143-52.
19. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71.
20. Miron VE, Ludwin SK, Darlington PJ, Jarjour A, Soliven B, Kennedy TE, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010; 176: 2682-94.
21. Miron VE, Schubart A, Antel JP. Central nervous systemdirected effects of FTY720 (fingolimod). J Neurol Sci 2008; 274: 13-7.
22. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323: 626-35.
23. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006; 108: 327-32.
24. McQualter JL, Bernard CC. Multiple sclerosis: a battle between destruction and repair. J Neurochem 2007; 100: 295-306.
25. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-17.
26. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-8.
27. Kipp M, Gingele S, Pott F, Clarner T, Van der Valk P, Denecke B, et al. BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions. Brain Behav Immun 2011; 25: 1554-68.
28. Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, et al. Identification of a microglia phenotype supportive of remyelination. Glia 2012; 60: 306-21.
29. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117: 77-93.
30. O'Sullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmacol Sci 2013; 34: 401-12.
31. Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis -critical appraisal of fingolimod. Ther Clin Risk Manag 2013; 9: 73-85.
32. Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, et al. How does fingolimod (Gilenya R) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol 2013; 4: 10.
33. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013; 328: 9-18.
34. Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010; 58: 1465-76.
35. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131: 3092-102.
36. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173-82.
37. Pilorget A, Demeule M, Barakat S, Marvaldi J, Luis J, Beliveau R. Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells. J Neurochem 2007; 100: 1203-10.
38. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, et al. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007; 19: 1754-64.
39. Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol 2014; 175: 359-72.
40. Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Health Patient Saf 2013; 5: 37-47.
41. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137-51.
42. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993; 116: 681-93.
43. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007; 21: 1503-14.
44. Kipp M, Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scler 2012; 18: 258-63.
45. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008; 65: 2702-20.
46. Williams A, Piaton G, Lubetzki C. Astrocytes -friends or foes in multiple sclerosis? Glia 2007; 55: 1300-12.
47. Sofroniew MV. Reactive astrocytes in neural repair and protection. Neuroscientist 2005; 11: 400-7.
48. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006; 49: 823-32.
49. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-77.
50. Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 2006; 53: 621-30.
51. Sheridan GK, Dev KK. S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia 2012; 60: 382-92.
52. Rouach N, Pebay A, Meme W, Cordier J, Ezan P, Etienne E, et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 2006; 23: 1453-64.
53. Wu C, Leong SY, Moore CS, Cui QL, Gris P, Bernier LP, et al. Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J Neuroinflammation 2013; 10: 41.
54. Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007; 102: 1151-61.
55. Gao F, Liu Y, Li X, Wang Y, Wei D, Jiang W. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 2012; 103: 187-96.
56. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011; 108: 751-6.
57. Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation 2011; 8: 76.
58. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 2013; 256: 13-8.
59. Norimatsu Y, Ohmori T, Kimura A, Madoiwa S, Mimuro J, Seichi A, et al. FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. Am J Pathol 2012; 180: 1625-35.
60. Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine- 1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004; 88: 1026-39.
61. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25: 11113-21.
62. Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstien S, et al. Differential transactivation of sphingosine- 1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004; 166: 381-92.
63. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, et al. Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One 2013; 8: e61988.
64. Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, et al. FTY720/fingolimod, a sphingosine analogue, reduces amyloid-beta production in neurons. PLoS One 2013; 8: e64050.
65. Asle-Rousta M, Kolahdooz Z, Oryan S, Ahmadiani A, Dargahi L. FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats. J Mol Neurosci 2013; 50: 524-32.
66. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Reuschel R, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323: 469-76.
67. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009; 19: 254-66.
68. Balatoni B, Storch MK, Swoboda EM, Schonborn V, Koziel A, Lambrou GN, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74: 307-16.
69. Papadopoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010; 88: 346-59.
70. Schubart AS, Howard L, Seabrook T. FTY720 suppresses ongoing EAE and promotes a remyelinating environment preventing axonal degeneration within the CNS. Neurology 2008; 70 (Suppl 1): A339.
71. Wang X, Brieland JK, Kim JH, Chen YJ, O'Neal J, O'Neil SP, et al. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice. NMR Biomed 2013; 26: 1742-50.
72. Schubart A, Seabrook T, Rausch M. CNS mediated effects of FTY720 (fingolimod). Neurology 2007; 68 (Suppl 1): S315.
73. Rossi S, Giudice TL, De Chiara V, Musella A, Studer V, Centonze D. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol 2012; 165: 861-9.
74. Anthony DC, Sibson NR, Leppert D, Piani-Meier D. Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal delayed-type hypersensitivity model of multiple sclerosis during the remission phase. Mult Scler 2010; 16 (Suppl 10): S283-4.
75. Nacer A, Movila A, Baer K, Mikolajczak SA, Kappe SH, Frevert U. Neuroimmunological blood brain barrier opening in experimental cerebral malaria. PLoS Pathog 2012; 8: e1002982.
76. Li MH, Hla T, Ferrer F. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer 2013; 60: 1418-23.
77. Stessin AM, Gursel DB, Schwartz A, Parashar B, Kulidzhanov FG, Sabbas AM, et al. FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells. Neurosci Lett 2012; 516: 253-8.
78. Hu Y, Lee X, Ji B, Guckian K, Apicco D, Pepinsky RB, et al. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol Cell Neurosci 2011; 48: 72-81.
79. Soliven B, Miron VE, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 2011; 76 (Suppl 3): S9-14.
80. Fernandez O, Rodriguez-Antiguedad A, Oreja-Guevara C, Garcia-Garcia M, Montalban X. Utilidad de los registros electronicos de medicamentos: registro espanol de pacientes tratados con fingolimod (Gilenya ®). Rev Neurol 2014; 58: 77-83.